[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349949-105":59,"doc-detail-349949-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","profiling-the-pancreatic-cancer-secretome-with-metabolic-glycoengineering","Profiling the pancreatic cancer secretome with metabolic glycoengineering","","Profiling the secretome for cancer biomarkers offers a minimally invasive route to detect and monitor disease, yet faces obstacles such as the secretome’s broad biomolecular dynamic range and the need for selective tumor marker detection. This study uses metabolic glycoengineering with the azido-tagged precursor 1,3,4-O-Bu3ManNAz to label the glycome of pancreatic near-normal and cancer cells and integrate MGE enrichment into conventional LC–MS/MS proteomics. The workflow identifies unique cancer-secreted proteins and additional putatively intracellular, non–N-glycosylated factors, including β-glucocerebrosidase and paladin. It also boosts extracellular vesicle production, enabling deeper EV-associated biomarker discovery from plasma of tumor-bearing mice.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/profiling-the-pancreatic-cancer-secretome-with-metabolic-glycoengineering/349949/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/profiling-the-pancreatic-cancer-secretome-with-metabolic-glycoengineering/349949.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is secretome profiling considered useful for pancreatic cancer biomarkers?","Question",{"text":112,"@type":113},"Secretome biomarkers can provide a minimally invasive way to detect and monitor cancer, reflecting tumor-derived molecular signatures. The study frames it as attractive despite analytical challenges.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does metabolic glycoengineering play in this workflow?",{"text":117,"@type":113},"Metabolic glycoengineering uses the azido-tagged precursor 1,3,4-O-Bu3ManNAz to label the glycome, enabling enrichment of secreted azido-labeled glycoconjugates. This is combined with LC–MS/MS proteomics to improve biomarker discovery.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the approach address extracellular vesicles (EVs) in pancreatic cancer?",{"text":121,"@type":113},"The study identifies EV-associated proteins and reports that ManNAc analogs used in the MGE-LC–MS/MS workflow enhance EV production. This creates a more complete secretome profile and supports EV-based biomarker discovery.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349949,1790176267,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","RESEARCH ARTICLE  \nProfiling the pancreatic cancer secretome with metabolic glycoengineering  \nReceived for publication, December 22, 2025, and in revised form, January 26, 2026 Published, Papers in Press, February 4, 2026 [https://doi.org/10.1016/j.jbc.2026.1](https://doi.org/10.1016/j.jbc.2026.1)11243  \nKris Dammen-Brower 1,2, Stanley Zhu 1,2, Christian Agatemor 1,2, Safiya Aafreen2, Vrinda Dharharma 1,2, Christopher T. Saeui 1,2, Hui Li3, Jian Song3, Matthew J. Buettner 1,2, Keith R. Kwagala 1,2, Hui Zhang4,  \nHoward E. Katz3, Guanshu Liu5,6,7, and Kevin J. Yarema 1,2,*  \nFrom the 1Translational Tissue Engineering Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 2Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 3Department of Materials Science and Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, Maryland, USA; 4Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA; 5F.M. Kirby Research Center, Kennedy Krieger Institute, Baltimore, Maryland, USA; 6Division of MR Research, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 7Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA  \nReviewed by members of the JBC Editorial Board. Edited by Robert Haltiwanger  \nProfiling the secretome for biomarkers offers an attractive, minimally invasive strategy to detect and monitor cancer. Several challenges, however, must be overcome, including the broad dynamic range of biomolecules in the secretome and the requirement for selective detection of tumor-associated markers. Here, we employed a metabolic glycoengineering (MGE) strategy, using 1,3,4-O-Bu3ManNAz, an azido-tagged, bio-orthogonal metabolic precursor of sialic acid, to label the glycome of pancreatic near-normal and cancer cells to improve conventional LC–MS/MS proteomics–based biomarker discovery. By using this “MGE-LC–MS/MS”approach that incorporates MGE enrichment into conventional LC–MS/MS proteomics, we identified several unique proteins from the secretomes of cancer cells evaluated in vitro. In addition to proteins known to be secreted, we identified several putatively intracellular, non–N-glycosylated proteins, such as β-glucocerebrosidase and paladin, linked to pancreatic cancer (PC) as well as proteins associated with extracellular vesicles (EVs) in PC, such as dCTP pyrophosphatase 1. The identification of EV-associated proteins was consistent with our discovery that ManNAc analogs used in the MGE-LC–MS/ MS workflow enhance EV production, creating a more complete secretome profile of PC cells. Pointing toward clinical relevance, we used MGE-LC–MS/MS to enrich PC-derived glycoproteins from plasma harvested from mice bearing xenografted human pancreatic tumors, unambiguously demonstrating that this approach can interrogate the secretomes of cancer cells for biomarker discovery. Finally, we discovered that MGE dramatically improved the production of EVs, which both aids in biomarker discovery (this study) and holds potential to facilitate biomanufacturing of these nascent drugs.  \n* For correspondence: Kevin J. Yarema, [kyarema1@jhu.edu](kyarema1@jhu.edu).  \nA lack of biomarkers for early stage pancreatic cancer (PC) contributes to a poor 5-year survival rate of less than 11%(1, 2). The only Food and Drug Administration–approved serum biomarker for this disease is the carbohydrate antigen 19-9, which has limited specificity and sensitivity (3–7). Motivated by compelling links between aberrant glycosylation and cancer (8–11), we reasoned that biomolecular engineering strategies that manipulate cellular glycans could facilitate the discovery of biomarkers with increased specificity and sensitivity. In particular, we exploited metabolic glycoengineering (MGE), a chemical biology techni","cbCaib0pZq4UeOmu","https://ap.wps.com/l/cbCaib0pZq4UeOmu","pdf",11174566,26,"English","# Profiling pancreatic cancer secretome and biomarker challenge\n## Metabolic glycoengineering strategy and labeling agent\n## MGE-LC–MS/MS workflow and protein identification\n## Extracellular vesicles and enhanced secretome coverage\n## In vivo plasma enrichment and biomarker relevance\n## Improved EV production and implications","[{\"question\":\"Why is secretome profiling considered useful for pancreatic cancer biomarkers?\",\"answer\":\"Secretome biomarkers can provide a minimally invasive way to detect and monitor cancer, reflecting tumor-derived molecular signatures. The study frames it as attractive despite analytical challenges.\"},{\"question\":\"What role does metabolic glycoengineering play in this workflow?\",\"answer\":\"Metabolic glycoengineering uses the azido-tagged precursor 1,3,4-O-Bu3ManNAz to label the glycome, enabling enrichment of secreted azido-labeled glycoconjugates. This is combined with LC–MS/MS proteomics to improve biomarker discovery.\"},{\"question\":\"How does the approach address extracellular vesicles (EVs) in pancreatic cancer?\",\"answer\":\"The study identifies EV-associated proteins and reports that ManNAc analogs used in the MGE-LC–MS/MS workflow enhance EV production. This creates a more complete secretome profile and supports EV-based biomarker discovery.\"}]","Profiling the pancreatic cancer secretome with metabolic glycoengineering | PDF",1790086420,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14ca816845370807eb3be96b8fb35444.webp",983,1296,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c957c72191b17abea3c04f8e0acb242d.webp",982,1294,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/27ecdb51eae4187f5677507cc9386c3d.webp",981,1293,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e349509f6610a02d4609ef63b7957b0d.webp",980,1292]